BIOMAT Database Logo BIOMAT Database Logo

Antimalarial activity of the anticancer histone deacetylase inhibitor SB939. 2012

Subathdrage D M Sumanadasa, and Christopher D Goodman, and Andrew J Lucke, and Tina Skinner-Adams, and Ishani Sahama, and Ashraful Haque, and Tram Anh Do, and Geoffrey I McFadden, and David P Fairlie, and Katherine T Andrews
Eskitis Institute for Cell and Molecular Therapies, Griffith University, Brisbane, Queensland, Australia.

Histone deacetylase (HDAC) enzymes posttranslationally modify lysines on histone and nonhistone proteins and play crucial roles in epigenetic regulation and other important cellular processes. HDAC inhibitors (e.g., suberoylanilide hydroxamic acid [SAHA; also known as vorinostat]) are used clinically to treat some cancers and are under investigation for use against many other diseases. Development of new HDAC inhibitors for noncancer indications has the potential to be accelerated by piggybacking onto cancer studies, as several HDAC inhibitors have undergone or are undergoing clinical trials. One such compound, SB939, is a new orally active hydroxamate-based HDAC inhibitor with an improved pharmacokinetic profile compared to that of SAHA. In this study, the in vitro and in vivo antiplasmodial activities of SB939 were investigated. SB939 was found to be a potent inhibitor of the growth of Plasmodium falciparum asexual-stage parasites in vitro (50% inhibitory concentration [IC(50)], 100 to 200 nM), causing hyperacetylation of parasite histone and nonhistone proteins. In combination with the aspartic protease inhibitor lopinavir, SB939 displayed additive activity. SB939 also potently inhibited the in vitro growth of exoerythrocytic-stage Plasmodium parasites in liver cells (IC(50), ~150 nM), suggesting that inhibitor targeting to multiple malaria parasite life cycle stages may be possible. In an experimental in vivo murine model of cerebral malaria, orally administered SB939 significantly inhibited P. berghei ANKA parasite growth, preventing development of cerebral malaria-like symptoms. These results identify SB939 as a potent new antimalarial HDAC inhibitor and underscore the potential of investigating next-generation anticancer HDAC inhibitors as prospective new drug leads for treatment of malaria.

UI MeSH Term Description Entries
D008288 Malaria A protozoan disease caused in humans by four species of the PLASMODIUM genus: PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM OVALE; and PLASMODIUM MALARIAE; and transmitted by the bite of an infected female mosquito of the genus ANOPHELES. Malaria is endemic in parts of Asia, Africa, Central and South America, Oceania, and certain Caribbean islands. It is characterized by extreme exhaustion associated with paroxysms of high FEVER; SWEATING; shaking CHILLS; and ANEMIA. Malaria in ANIMALS is caused by other species of plasmodia. Marsh Fever,Plasmodium Infections,Remittent Fever,Infections, Plasmodium,Paludism,Fever, Marsh,Fever, Remittent,Infection, Plasmodium,Plasmodium Infection
D010963 Plasmodium falciparum A species of protozoa that is the causal agent of falciparum malaria (MALARIA, FALCIPARUM). It is most prevalent in the tropics and subtropics. Plasmodium falciparums,falciparums, Plasmodium
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000962 Antimalarials Agents used in the treatment of malaria. They are usually classified on the basis of their action against plasmodia at different stages in their life cycle in the human. (From AMA, Drug Evaluations Annual, 1992, p1585) Anti-Malarial,Antimalarial,Antimalarial Agent,Antimalarial Drug,Anti-Malarials,Antimalarial Agents,Antimalarial Drugs,Agent, Antimalarial,Agents, Antimalarial,Anti Malarial,Anti Malarials,Drug, Antimalarial,Drugs, Antimalarial
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D001562 Benzimidazoles Compounds with a BENZENE fused to IMIDAZOLES.
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus
D054022 Cerebrum Derived from TELENCEPHALON, cerebrum is composed of a right and a left hemisphere. Each contains an outer cerebral cortex and a subcortical basal ganglia. The cerebrum includes all parts within the skull except the MEDULLA OBLONGATA, the PONS, and the CEREBELLUM. Cerebral functions include sensorimotor, emotional, and intellectual activities. Cerebra,Cerebral Hemispheres,Left Cerebral Hemisphere,Right Cerebral Hemisphere,Cerebral Hemisphere,Cerebral Hemisphere, Left,Cerebral Hemisphere, Right
D056572 Histone Deacetylase Inhibitors Compounds that inhibit HISTONE DEACETYLASES. This class of drugs may influence gene expression by increasing the level of acetylated HISTONES in specific CHROMATIN domains. HDAC Inhibitor,HDAC Inhibitors,Histone Deacetylase Inhibitor,Deacetylase Inhibitor, Histone,Deacetylase Inhibitors, Histone,Inhibitor, HDAC,Inhibitor, Histone Deacetylase,Inhibitors, HDAC,Inhibitors, Histone Deacetylase

Related Publications

Subathdrage D M Sumanadasa, and Christopher D Goodman, and Andrew J Lucke, and Tina Skinner-Adams, and Ishani Sahama, and Ashraful Haque, and Tram Anh Do, and Geoffrey I McFadden, and David P Fairlie, and Katherine T Andrews
Therapeutic activity of the histone deacetylase inhibitor SB939 on renal fibrosis.
January 2017, International immunopharmacology,
Subathdrage D M Sumanadasa, and Christopher D Goodman, and Andrew J Lucke, and Tina Skinner-Adams, and Ishani Sahama, and Ashraful Haque, and Tram Anh Do, and Geoffrey I McFadden, and David P Fairlie, and Katherine T Andrews
Potent antimalarial activity of histone deacetylase inhibitor analogues.
April 2008, Antimicrobial agents and chemotherapy,
Subathdrage D M Sumanadasa, and Christopher D Goodman, and Andrew J Lucke, and Tina Skinner-Adams, and Ishani Sahama, and Ashraful Haque, and Tram Anh Do, and Geoffrey I McFadden, and David P Fairlie, and Katherine T Andrews
Anticancer activity of topical ointments with histone deacetylase inhibitor, trichostatin A.
September 2020, Advances in clinical and experimental medicine : official organ Wroclaw Medical University,
Subathdrage D M Sumanadasa, and Christopher D Goodman, and Andrew J Lucke, and Tina Skinner-Adams, and Ishani Sahama, and Ashraful Haque, and Tram Anh Do, and Geoffrey I McFadden, and David P Fairlie, and Katherine T Andrews
NBM-HD-1: A Novel Histone Deacetylase Inhibitor with Anticancer Activity.
January 2012, Evidence-based complementary and alternative medicine : eCAM,
Subathdrage D M Sumanadasa, and Christopher D Goodman, and Andrew J Lucke, and Tina Skinner-Adams, and Ishani Sahama, and Ashraful Haque, and Tram Anh Do, and Geoffrey I McFadden, and David P Fairlie, and Katherine T Andrews
Antitheilerial Activity of the Anticancer Histone Deacetylase Inhibitors.
January 2021, Frontiers in microbiology,
Subathdrage D M Sumanadasa, and Christopher D Goodman, and Andrew J Lucke, and Tina Skinner-Adams, and Ishani Sahama, and Ashraful Haque, and Tram Anh Do, and Geoffrey I McFadden, and David P Fairlie, and Katherine T Andrews
Selective Histone Deacetylase Inhibitors with Anticancer Activity.
January 2016, Current topics in medicinal chemistry,
Subathdrage D M Sumanadasa, and Christopher D Goodman, and Andrew J Lucke, and Tina Skinner-Adams, and Ishani Sahama, and Ashraful Haque, and Tram Anh Do, and Geoffrey I McFadden, and David P Fairlie, and Katherine T Andrews
Depsipeptide (FK228) as a novel histone deacetylase inhibitor: mechanism of action and anticancer activity.
October 2007, Mini reviews in medicinal chemistry,
Subathdrage D M Sumanadasa, and Christopher D Goodman, and Andrew J Lucke, and Tina Skinner-Adams, and Ishani Sahama, and Ashraful Haque, and Tram Anh Do, and Geoffrey I McFadden, and David P Fairlie, and Katherine T Andrews
Antimalarial activity of phenylthiazolyl-bearing hydroxamate-based histone deacetylase inhibitors.
October 2008, Antimicrobial agents and chemotherapy,
Subathdrage D M Sumanadasa, and Christopher D Goodman, and Andrew J Lucke, and Tina Skinner-Adams, and Ishani Sahama, and Ashraful Haque, and Tram Anh Do, and Geoffrey I McFadden, and David P Fairlie, and Katherine T Andrews
Preclinical metabolism and disposition of SB939 (Pracinostat), an orally active histone deacetylase inhibitor, and prediction of human pharmacokinetics.
December 2011, Drug metabolism and disposition: the biological fate of chemicals,
Subathdrage D M Sumanadasa, and Christopher D Goodman, and Andrew J Lucke, and Tina Skinner-Adams, and Ishani Sahama, and Ashraful Haque, and Tram Anh Do, and Geoffrey I McFadden, and David P Fairlie, and Katherine T Andrews
Enhancing the anticancer effect of the histone deacetylase inhibitor by activating transglutaminase.
November 2012, European journal of cancer (Oxford, England : 1990),
Copied contents to your clipboard!